Enrique Grande

Summary

Publications

  1. doi request reprint Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)
    Enrique Grande
    Medical Oncology Service, Ramon y Cajal University Hospital, Madrid, Spain
    Clin Transl Oncol 12:481-92. 2010
  2. doi request reprint Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor
    Enrique Grande
    Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain
    Anticancer Drugs 22:477-9. 2011
  3. doi request reprint Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
    E Grande
    Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid
    Ann Oncol 26:1987-93. 2015
  4. ncbi request reprint A comprehensive review of poorly differentiated neuroendocrine carcinomas (pdNECs): a niche to find novel opportunities
    Pablo Reguera
    Dr Enrique Grande Servicio de Oncología Medica, Hospital Ramon y Cajal, Carretera de Colmenar Km 9, 1 28034 Madrid, Spain
    Curr Pharm Des 20:6644-51. 2014
  5. pmc Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice
    Daniel Castellano
    Medical Oncology Department, Ramon y Cajal University Hospital, Ctra, de Colmenar Viejo km, 9, 100, 28034 Madrid, Spain
    BMC Cancer 14:779. 2014
  6. pmc Thyroid cancer: molecular aspects and new therapeutic strategies
    Enrique Grande
    Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain
    J Thyroid Res 2012:847108. 2012
  7. pmc Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies
    Enrique Grande
    Servicio de Oncologia Medica, Hospital Ramon y Cajal, Carretera de Colmenar Viejo Km 9 100, 28034, Madrid, Spain
    Adv Ther 30:945-66. 2013
  8. doi request reprint New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies
    Enrique Grande
    Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
    Expert Rev Anticancer Ther 12:457-67. 2012
  9. doi request reprint Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?
    Enrique Grande
    Servicio de Oncologia Medica, Hospital Universitario Ramón y Cajal de Madrid, Madrid, Spain
    Cancer Metastasis Rev 31:47-53. 2012
  10. doi request reprint Targeting oncogenic ALK: a promising strategy for cancer treatment
    Enrique Grande
    Gastrointestinal and Early Drug Development Unit, Servicio de Oncologia Medica, Hospital Ramon y Cajal, Carretera de Colmenar Viejo Km 9 100, 28034, Madrid, Spain
    Mol Cancer Ther 10:569-79. 2011

Detail Information

Publications23

  1. doi request reprint Advances in the therapy of gastroenteropancreatic-neuroendocrine tumours (GEP-NETs)
    Enrique Grande
    Medical Oncology Service, Ramon y Cajal University Hospital, Madrid, Spain
    Clin Transl Oncol 12:481-92. 2010
    ..In fact, mTOR inhibitors have shown activity in uncontrolled trials, and large, randomised trial results will be available shortly. In this article, we summarise the most recent available data on medical therapy for GEPNETs...
  2. doi request reprint Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor
    Enrique Grande
    Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain
    Anticancer Drugs 22:477-9. 2011
    ..To our knowledge, this is the first reported case of treatment with sunitinib in a patient with PNET in response to Choi criteria...
  3. doi request reprint Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
    E Grande
    Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid
    Ann Oncol 26:1987-93. 2015
    ..The management of advanced neuroendocrine tumors (NETs) has recently changed. We assessed the activity of pazopanib after failure of other systemic treatments in advanced NETs...
  4. ncbi request reprint A comprehensive review of poorly differentiated neuroendocrine carcinomas (pdNECs): a niche to find novel opportunities
    Pablo Reguera
    Dr Enrique Grande Servicio de Oncología Medica, Hospital Ramon y Cajal, Carretera de Colmenar Km 9, 1 28034 Madrid, Spain
    Curr Pharm Des 20:6644-51. 2014
    ..In this review we summarize the current background behind the management of poorly differentiated neuroendocrine carcinomas in daily clinical practice. ..
  5. pmc Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice
    Daniel Castellano
    Medical Oncology Department, Ramon y Cajal University Hospital, Ctra, de Colmenar Viejo km, 9, 100, 28034 Madrid, Spain
    BMC Cancer 14:779. 2014
    ..Vinflunine is approved by the European Medicine Agency (EMA) but, up to now, limited experience has been reported outside clinical trials...
  6. pmc Thyroid cancer: molecular aspects and new therapeutic strategies
    Enrique Grande
    Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain
    J Thyroid Res 2012:847108. 2012
    ..The correct molecular characterization of patients with thyroid cancer is thought to be a key aspect for the future clinical management of these patients...
  7. pmc Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies
    Enrique Grande
    Servicio de Oncologia Medica, Hospital Ramon y Cajal, Carretera de Colmenar Viejo Km 9 100, 28034, Madrid, Spain
    Adv Ther 30:945-66. 2013
    ....
  8. doi request reprint New targeted approaches against the ubiquitin-proteasome system in gastrointestinal malignancies
    Enrique Grande
    Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
    Expert Rev Anticancer Ther 12:457-67. 2012
    ..In this article we review the rationale for the use of novel ubiquitin-proteasome system inhibitors in gastrointestinal malignancies...
  9. doi request reprint Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist?
    Enrique Grande
    Servicio de Oncologia Medica, Hospital Universitario Ramón y Cajal de Madrid, Madrid, Spain
    Cancer Metastasis Rev 31:47-53. 2012
    ..New therapeutic approaches in the field of CSCs seem to have a clear role in the treatment of medulloblastomas and basal cell carcinomas, but their future value in other solid tumor types including NETs remains unclear...
  10. doi request reprint Targeting oncogenic ALK: a promising strategy for cancer treatment
    Enrique Grande
    Gastrointestinal and Early Drug Development Unit, Servicio de Oncologia Medica, Hospital Ramon y Cajal, Carretera de Colmenar Viejo Km 9 100, 28034, Madrid, Spain
    Mol Cancer Ther 10:569-79. 2011
    ....
  11. doi request reprint Complete response to sunitinib in a patient with relapsed irresectable renal cell carcinoma
    María Angeles Vaz
    Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain
    Anticancer Drugs 22:817-21. 2011
    ..Otherwise after discontinuing sunitinib, the patient had a relapse on the same location; sunitinib has been resumed and was again found to be effective...
  12. ncbi request reprint Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib
    Luis Paz-Ares
    Oncology Department, Hospital 12 de Octubre, Madrid, Spain
    Clin Transl Oncol 10:831-9. 2008
    ..The purpose of this study is to assess the cost-effectiveness of sunitinib vs. best supportive care (BSC) in GIST as a second- line treatment, from the perspective of the Spanish National Health System...
  13. doi request reprint Renal cell carcinoma: complete pathological response in a patient with gastric metastasis of renal cell carcinoma
    Rosario Garcia-Campelo
    Medical Oncology Service, University Hospital Complex, A Coruna, Spain
    Anticancer Drugs 21:S13-5. 2010
    ..The whole-body CT did not reveal any other abnormality except for the known lung nodes. PET scan six months after treatment confirmed complete gastric response...
  14. doi request reprint The potential role of sunitinib in gastrointestinal cancers other than GIST
    Cristina Gravalos
    Medical Oncology Department, 12 de Octubre Universitary Hospital, Avda de Andalucía s n Km 5 400, 28041 Madrid, Spain
    Crit Rev Oncol Hematol 76:36-43. 2010
    ....
  15. doi request reprint Sorafenib in metastatic thyroid cancer
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Endocr Relat Cancer 19:209-16. 2012
    ..033). In this retrospective trial, sorafenib showed antitumor efficacy in all histological subtypes of thyroid cancer, warranting further development in this setting...
  16. doi request reprint Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients
    Daniel Castellano
    Medical Oncology Department, 12 de Octubre University Hospital, Av Córdoba Km 5, 4, PO Box 28041, Madrid, Spain
    Expert Opin Pharmacother 12:2433-9. 2011
    ..Sunitinib has shown activity in CRPC and at the time of this analysis there was no standard therapy for docetaxel-refractory CRPC...
  17. doi request reprint Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development
    Rocio Garcia-Carbonero
    Medical Oncology Department, Hospital Universitario Doce de Octubre, Center affiliated to the Red Temática de Investigación Cooperativa en Cancer RTICC, Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, Av Cordoba Km 5 4, 28041, Madrid, Spain
    Cancer Metastasis Rev 34:823-42. 2015
    ....
  18. doi request reprint Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis
    Jaume Capdevila
    Medical Oncology Department, Vall d Hebron University Hospital, Autonomous University of Barcelona, P Vall d Hebron 119 129, 08035, Barcelona, Spain
    BMC Cancer 15:495. 2015
    ..Herein, we investigate the use of these treatment combinations in clinical practice...
  19. doi request reprint Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors
    Daniel Castellano
    Departamento de Oncología Médica, Hospital Universitario 12 de Octubre, Avda de Cordoba s n, 28041, Madrid, Spain
    Cancer Chemother Pharmacol 75:1099-114. 2015
    ..There is therefore a need to establish a consensus for the treatment of this disease and to provide evidence-based clinical recommendations and algorithms to optimize and individualize the treatment and follow-up for these patients. ..
  20. doi request reprint Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach?
    Javier Molina-Cerrillo
    Medical Oncology Department, Ramon y Cajal University Hospital, Madrid, Spain
    Clin Genitourin Cancer 13:493-8. 2015
    ..Further multicenter comparative studies are needed to devise a better treatment strategy for patients with this rare histologic tumor subtype...
  21. pmc The dual kinase complex FAK-Src as a promising therapeutic target in cancer
    Victoria Bolós
    Pfizer Oncology, Madrid, Spain
    Onco Targets Ther 3:83-97. 2010
    ....
  22. ncbi request reprint Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer
    José A García-Sáenz
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Clin Breast Cancer 6:325-9. 2005
    ..To determine the activity of successive trastuzumab-containing regimens in HER2-overexpressing metastatic breast cancer (MBC) as well as the response rate (RR), time to progression (TTP), and predictive factors for response...